Home › Research › Disparities
Cholinesterase inhibitors for patients with dementia: Patterns of prescribing and disparities in treatment
Rachel J. Heo, Ahmed Negida, Matthew J. Barrett, Ella A. B. Chrenka, Ece Bayram, Joseph P. M. Kane, Ann M. Werner, Rebecca C. Rossom et al.. Journal of Alzheimer s Disease, 2026-01-13
Topic: Risk, prevention and care in population studies
Plain-language summary
BackgroundCholinesterase inhibitors (ChEIs) are cornerstones of the symptomatic treatment of Alzheimer's disease (AD) and dementia with Lewy bodies (DLB) and are also prescribed for vascular dementia (VaD). Despite their widespread use, patterns of ChEI prescribing are unclear.ObjectiveOur objective was to examine the prevalence, timing, and types of ChEI prescriptions before and after dementia diagnosis.MethodsWe analyzed electronic health record and claims data for patients diagnosed with AD, DLB, or VaD between October 2015 and August 2022 from a large U.S. healthcare system. ChEI claims (donepezil, rivastigmine, galantamine) were identified in the ±3 years surrounding dementia diagnosis. Repeated measures logistic regression was used to estimate the likelihood of ChEI fills by time-period, dementia type, and time x dementia type interaction to determine if change in prescription patterns significantly differed by diagnosis.ResultsAmong 3166 eligible patients, DLB had the highest prevalence of ChEIs both pre-and post-diagnosis compared to patients with AD and VaD. Post-diagnosis, donepezil was the most common, while galantamine use was sparse. After adjusting for demographics, patients with VaD had lower rates of ChEIs relative to AD (OR: 0.34, 95% CI 0.26-0.45). In the fully adjusted model, females (OR: 0.81, 95% CI: 0.71-0.91) and patients from ethnoracially minoritized populations (OR: 0.74, 95% CI: 0.62-0.88) were less likely to fill ChEI prescriptions.ConclusionsDonepezil was the most frequently filled ChEI across dementias. Patients with DLB had the highest prevalence of ChEIs pre- and post-diagnosis. The potential disparities in treatment we identified should be investigated further.
What this study adds
Evidence grade: Low
This study of prescribing patterns found that among patients with dementia, those with vascular dementia had lower rates of cholinesterase inhibitors relative to Alzheimer's disease, and females and patients from ethnoracially minoritized populations also had lower rates. Reported effect size: OR: 0.34; OR: 0.81; OR: 0.74.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Heo, R. J., Negida, A., Barrett, M. J., Chrenka, E. A. B., Bayram, E., Kane, J. P. M., et al. (2026). Cholinesterase inhibitors for patients with dementia: Patterns of prescribing and disparities in treatment. Journal of Alzheimer s Disease. https://doi.org/10.1177/13872877251411418
Vancouver
Heo RJ, Negida A, Barrett MJ, Chrenka EAB, Bayram E, Kane JPM, et al. Cholinesterase inhibitors for patients with dementia: Patterns of prescribing and disparities in treatment. Journal of Alzheimer s Disease. 2026. doi:10.1177/13872877251411418. PMID: 41527747.
BibTeX
@article{heo2026-41527747,
author = {Heo, Rachel J. and Negida, Ahmed and Barrett, Matthew J. and Chrenka, Ella A. B. and Bayram, Ece and Kane, Joseph P. M. and Werner, Ann M. and Rossom, Rebecca C. and others},
title = {{Cholinesterase inhibitors for patients with dementia: Patterns of prescribing and disparities in treatment}},
journal = {Journal of Alzheimer s Disease},
year = {2026},
doi = {10.1177/13872877251411418},
pmid = {41527747},
url = {https://doi.org/10.1177/13872877251411418}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Repeated measures logistic regression was used to estimate the likelihood of ChEI fills by time-period, dementia type, and time x dementia type interaction to determine if change in prescription patterns significantly differed by diagnosis.ResultsAmong 3166 eligible patients, DLB had the highest prevalence of ChEIs both pre-and post-diagnosis compared to patients with AD and VaD.
Why it matters
This study of prescribing patterns found that among patients with dementia, those with vascular dementia had lower rates of cholinesterase inhibitors relative to Alzheimer's disease, and females and patients from ethnoracially minoritized populations also had lower rates. It shows disparities in who receives these symptomatic treatments.
New to this subject? Start with our plain-English guide: Disparities →
Study details
- Effect sizeOR: 0.34; OR: 0.81; OR: 0.74
- Evidence strengthLow
How this study scored 40/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of Alzheimer s Disease) |
| Journal's citation record | 2 / 4 | Journal of Alzheimer s Disease: journal h-index 218 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 1 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.5 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 3 / 6 | Cited 4.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Kathryn A Wyman‐Chick: h-index 13 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Virginia Commonwealth University: institution h-index 851 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 5 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41527747) |
| Free to read | 2 / 2 | Free to read |
| Total | 40 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1177/13872877251411418
- PubMed: 41527747
- Original source →
- Free full text: Research Portal (Queen's University Belfast) →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Disparities from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.